Organization Profile

You just read:

New immunotherapy Opdivo™ (nivolumab) first PD-1 inhibitor to demonstrate superior overall survival versus standard of care (docetaxel) in previously treated non-squamous non-small cell lung cancer in pivotal phase 3 trial

News provided by

Bristol-Myers Squibb Canada

Jun 03, 2015, 05:59 ET